Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINJECTIONGeneric

CITANEST FORTE

EPINEPHRINE BITARTRATE; PRILOCAINE HYDROCHLORIDE

Standard Dose
0.005MG/ML;4%
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Discontinued
Summary

Approval overview CITANEST FORTE is listed in Drugs@FDA under application 014763 (NDA).

Review priority: PRIORITY Marketing status: Discontinued Active ingredient EPINEPHRINE BITARTRATE; PRILOCAINE HYDROCHLORIDE Form and strength INJECTABLE;INJECTION - 0.005MG/ML;4% Sponsor ASTRAZENECA Submission history Latest submission status date: 2000-12-01 00:00:00.

Structured Monograph

Clinical summary

Approval overview CITANEST FORTE is listed in Drugs@FDA under application 014763 (NDA). Review priority: PRIORITY Marketing status: Discontinued Active ingredient EPINEPHRINE BITARTRATE; PRILOCAINE HYDROCHLORIDE Form and strength INJECTABLE;INJECTION - 0.005MG/ML;4% Sponsor ASTRAZENECA Submission history Latest submission status date: 2000-12-01 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: PRIORITY

Interaction Notes

  • No interaction notes stored yet.